Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. This review highlights ten promising antihypertensive drug candidates with the potential to address pulmonary arterial hypertension (PAH), resistant hypertension and uncontrolled hypertension. Aprocitentan, developed by Janssen NYSE:JNJ) and Idorsia (SIX:IDIA), is an experimental oral drug designed to treat resistant hypertension. As a dual endothelin…

Pfizer Inc. (NYSE:PFE) is abandoning plans to develop an investigational antisense therapy known as vupanorsen for potential use for cardiovascular indications and severe hypertriglyceridemia (SHTG). The company had projected that vupanorsen could generate up to $3 billion in peak sales. Pfizer is returning development rights of the drug to Ionis Pharmaceuticals (NSDQ:IONS), from whom it…